Update on adjuvant interferon therapy for high-risk melanoma.

Oncology (Williston Park, N.Y.)

Volumn 16, Issue 9, 2002, Pages

  Agarwala, Sanjiv S ^a   Kirkwood, John M ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; MELANOMA; MULTIMODALITY CANCER THERAPY; REVIEW; SKIN TUMOR; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; HUMANS; INTERFERON ALFA-2B; MELANOMA; NEOPLASM RECURRENCE, LOCAL; SKIN NEOPLASMS;

EID: 0036727690     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)